Pulmonary Embolism Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The pulmonary embolism market size has grown rapidly in recent years. It will grow from $2.03 billion in 2024 to $2.27 billion in 2025 at a compound annual growth rate (CAGR) of 11.9%. The growth in the historic period can be attributed to anticoagulant therapies, research and clinical trials, pulmonary embolism awareness, vte prophylaxis.

The pulmonary embolism market size is expected to see rapid growth in the next few years. It will grow to $3.63 billion in 2029 at a compound annual growth rate (CAGR) of 12.5%. The growth in the forecast period can be attributed to targeted therapies, telemedicine and remote monitoring, health equity initiatives, global health initiatives. Major trends in the forecast period include artificial intelligence in diagnosis, novel anticoagulants, pulmonary embolism response teams, patient-centered care.

The burgeoning prevalence of blood clots is anticipated to be a driving force behind the growth of the pulmonary embolism market in the foreseeable future. Blood clots, medically referred to as thrombi, manifest as gel-like or semi-solid masses within blood vessels. The presence of blood clots escalates the risk of pulmonary embolism by impeding the natural flow of blood to the lungs, causing a blockage. These clots are typically observed in the deep veins of the legs, significantly increasing the likelihood of pulmonary embolism. As an illustration, a Gavi, the Vaccine Alliance article from April 2022 reported a thirty-three-fold surge in the potential occurrence of life-threatening lung clots and a five-fold increase in deep vein thrombosis risk within thirty days after COVID-19 exposure. Consequently, the escalating prevalence of blood clots is a key driver for the growth of the pulmonary embolism market.

The growing prevalence of cancer is expected to drive the growth of the pulmonary embolism market. Cancer refers to a group of diseases marked by the uncontrolled and abnormal growth of cells in the body. The rising incidence of cancer increases the risk of blood clots, such as pulmonary embolism, among cancer patients, leading to higher demand for diagnostics and treatments, including specialized medications. For example, in January 2024, the American Cancer Society, a US-based nonprofit organization, reported that the number of cancer cases rose to 2,001,140 in 2024, up from 1,958,310 in 2023, reflecting an increase of 2.19%. As a result, the increasing prevalence of cancer is driving the expansion of the pulmonary embolism market.

Prominent companies operating in the pulmonary embolism market are dedicated to introducing cutting-edge products such as the Triever16 Curve catheter and the RevCore thrombectomy catheter to maintain a competitive edge. As of June 2023, Inari Medical Inc., a US-based medical device company, has launched the Triever16 Curve catheter and the RevCore thrombectomy catheter. The innovative Triever16 Curve catheter is specially designed for peripheral thrombectomy and pulmonary embolism procedures. Its high trackability and pre-shaped curve facilitate focused aspiration. Moreover, the catheter's unique design offers easy access to larger and more powerful 20F or 24F catheters. On the other hand, the RevCore thrombectomy catheter has been developed for the treatment of venous in-stent thrombosis. This mechanical thrombectomy device utilizes a nitinol basket for capturing and removing blood clots, enhancing the safety and efficacy of pulmonary embolism procedures.

In February 2022, Boston Scientific International, a U.S.-based medical device company, acquired Baylis Medical Company Inc. for $1.75 billion. This acquisition strengthens Boston Scientific's portfolio by enhancing its offerings in structural heart disease and electrophysiology, including advanced transseptal access solutions. Baylis Medical Company Inc., a Canada-based medical device company, specializes in pulmonary embolism interventional tools.

Major companies operating in the pulmonary embolism market are Pfizer Inc., Johnson and Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck And Co.Inc., Novartis AG, Bayer AG, Sanofi S.A., Bristol Myers Squibb Company, GSK PLC, Abbott Laboratories, AstraZeneca PLC, Medtronic PLC, Eli Lilly and Company, Gilead Sciences Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Daiichi Sankyo Co. Ltd., Boehringer Ingelheim International GmbH, Mitsubishi Tanabe Pharma Corporation, Genentech Inc., Hikma Pharmaceuticals PLC, Aspen Pharmacare Holdings Limited, Nippon Shinyaku Co. Ltd., Penumbra Inc., Fresenius Kabi AG, Inari Medical Inc., AngioDynamics Inc., Otsuka Pharmaceutical Co. Ltd.

North America was the largest region in the pulmonary embolism market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pulmonary embolism report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the pulmonary embolism market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The pulmonary embolism market consists of revenues earned by entities by providing services such as medical management, thrombolytic therapy, monitoring and oxygen therapy services. The market value includes the value of related goods sold by the service provider or included within the service offering. The pulmonary embolism market also includes sales of diagnostic imaging equipment, oxygen delivery devices, interventional devices, medical alert systems and pulse oximeters. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

A pulmonary embolism is a condition characterized by the blockage of the pulmonary artery, which carries blood from the heart to the lungs. This blockage typically results from a blood clot that has traveled from another part of the body, most commonly the legs. Symptoms of a pulmonary embolism can vary, ranging from sudden shortness of breath to chest pain, coughing up blood or bloody mucus, and other signs, with the severity depending on the size and location of the clot.

The primary types of treatment for pulmonary embolism encompass medications, mechanical devices, surgery, and other therapeutic interventions. Medications are substances used for medical purposes to treat, manage, prevent, or alleviate various medical conditions and illnesses. Diagnosis of a pulmonary embolism involves various methods, including chest X-rays, electrocardiograms (ECGs), magnetic resonance imaging (MRI), computed tomography scans, pulmonary angiography, venography, venous ultrasound, D-Dimer tests, and others. Symptoms may include shortness of breath, chest pain, cough, irregular heartbeat, dizziness, fever, cyanosis, and more. Medications for treating pulmonary embolism are primarily distributed through hospital pharmacies, retail pharmacies, online pharmacies, and other relevant channels. Healthcare providers in hospitals, specialty clinics, homecare settings, and other medical facilities typically manage the treatment of pulmonary embolism.

The pulmonary embolism market research report is one of a series of new reports that provides pulmonary embolism market statistics, including pulmonary embolism industry global market size, regional shares, competitors with a pulmonary embolism market share, detailed pulmonary embolism market segments, market trends and opportunities and any further data you may need to thrive in the pulmonary embolism industry. This pulmonary embolism market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.